Indication
Herpes Simplex Type 2
1 clinical trial
1 product
Product
BNT163Clinical trial
Phase I, Randomized, Observer-blinded, Placebo-controlled, 2-part, Dose Escalation and Expanded Safety Evaluation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Prophylactic Vaccine for the Prevention of Genital Lesions Caused by Herpes Simplex Virus (HSV)-2 and Potentially HSV-1Status: Recruiting, Estimated PCD: 2025-12-01